indication of the approximate time requested to make their presentation. The agenda for the public webinar will be made available on the Internet at *http://www.fda.gov/Drugs/NewsEvents/ ucm466461.htm*.

## **III. Transcripts**

Please be advised that as soon as a webinar transcript is available, FDA will post it at *http://www.fda.gov/Drugs/ NewsEvents/ucm466461.htm*.

Dated: October 29, 2015.

# Leslie Kux,

Associate Commissioner for Policy. [FR Doc. 2015–27953 Filed 11–2–15; 8:45 am] BILLING CODE 4164–01–P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

[Docket No. FDA-2015-N-0001]

## Science Board to the Food and Drug Administration Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

### ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Science Board to the Food and Drug Administration (Science Board).

General Function of the Committee: The Science Board provides advice to the Commissioner of Food and Drugs and other appropriate officials on specific, complex scientific and technical issues important to the FDA and its mission, including emerging issues within the scientific community. Additionally, the Science Board provides advice to the Agency on keeping pace with technical and scientific developments including in regulatory science, input into the Agency's research agenda and on upgrading its scientific and research facilities and training opportunities. It will also provide, where requested, expert review of Agency sponsored intramural and extramural scientific research programs.

*Date and Time:* The meeting will be held on November 18, 2015, from 9 a.m. until 4 p.m.

*Location:* Food and Drug Administration, White Oak 31, Rm. 1503, Section A, 10903 New Hampshire Ave., Silver Spring, MD 20993. For those unable to attend in person, the meeting will also be webcast. The link for the webcast is available at *https:// collaboration.fda.gov/science board1115/*. Answers to commonly asked questions including information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: *http://www.fda.gov/Advisory Committees/AboutAdvisoryCommittees/ ucm408555.htm.* 

Contact Person: Rakesh Raghuwanshi, Office of the Chief Scientist, Office of the Commissioner, Food and Drug Administration, White Oak Bldg. 1 Rm. 3309, 10903 New Hampshire Ave., Silver Spring, MD 20993, 301-796-4769, rakesh.raghuwanshi@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301–443–0572 in the Washington, DC area). A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's Web site at http://www.fda.gov/Advisory *Committees/default.htm* and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

Agenda: The Science Board will be provided with updates from the Center for Food Safety and Applied Nutrition, Centers for Excellence in Regulatory Science and Innovation, Evaluation Subcommittee and the ORA Food Emergency Response Network Evaluation Subcommittee. The Board will hear about the scope of FDA's involvement in precision medicine, as well as an overview of specific health informatics initiatives including precision FDA, Open FDA, and Chillax. The Board will also hear about FDA's laboratory safety initiative. A recipient of one of the FY 2014 Scientific Achievement Awards (selected by the Board) will provide an overview of the activities for which the award was given.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at *http://www.fda.gov/ AdvisoryCommittees/Calendar/ default.htm.* Scroll down to the appropriate advisory committee meeting link.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before November 11, 2015. Oral presentations from the public will be scheduled between approximately 3 and 4 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before November 11, 2015. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to November 13, 2015.

Persons attending FDA's advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Rakesh Raghuwanshi at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/Advisory Committees/AboutAdvisoryCommittees/ ucm111462.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: October 28, 2015.

#### Jill Hartzler Warner,

Associate Commissioner for Special Medical Programs.

[FR Doc. 2015–27957 Filed 11–2–15; 8:45 am] BILLING CODE 4164–01–P